Israel Englander’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.4M | Sell |
42,000
-16,000
| -28% | -$876K | ﹤0.01% | 3668 |
|
|
2026
Q1 | $3.28M | Sell |
58,000
-100,000
| -63% | -$5.83M | ﹤0.01% | 3391 |
|
|
2025
Q4 | $9.39M | Buy |
158,000
+46,100
| +41% | +$2.51M | ﹤0.01% | 2332 |
|
|
2025
Q3 | $6.06M | Buy |
+111,900
| New | +$6.4M | ﹤0.01% | 2936 |
|
|
2025
Q2 | – | Sell |
-100,000
| Closed | -$7.07M | – | 5872 |
|
|
2025
Q1 | $7.07M | Buy |
100,000
+59,500
| +147% | +$4M | ﹤0.01% | 2522 |
|
|
2024
Q4 | $2.66M | Sell |
40,500
-51,500
| -56% | -$3.45M | ﹤0.01% | 3399 |
|
|
2024
Q3 | $6.47M | Buy |
92,000
+44,800
| +95% | +$3.74M | ﹤0.01% | 2614 |
|
|
2024
Q2 | $3.89M | Sell |
47,200
-289,100
| -86% | -$24.1M | ﹤0.01% | 2951 |
|
|
2024
Q1 | $29.4M | Buy |
336,300
+190,100
| +130% | +$17M | 0.01% | 1216 |
|
|
2023
Q4 | $14.1M | Buy |
146,200
+82,800
| +131% | +$7.33M | 0.01% | 1875 |
|
|
2023
Q3 | $5.61M | Buy |
63,400
+43,400
| +217% | +$3.86M | ﹤0.01% | 2594 |
|
|
2023
Q2 | $1.73M | Sell |
20,000
-55,300
| -73% | -$5.2M | ﹤0.01% | 3611 |
|
|
2023
Q1 | $7.32M | Buy |
+75,300
| New | +$7.81M | ﹤0.01% | 2257 |
|
|
2022
Q4 | – | Sell |
-10,000
| Closed | -$848K | – | 6580 |
|
|
2022
Q3 | $848K | Buy |
+10,000
| New | +$890K | ﹤0.01% | 4477 |
|
|
2021
Q4 | – | Sell |
-20,000
| Closed | -$1.55M | – | 6801 |
|
|
2021
Q3 | $1.55M | Buy |
+20,000
| New | +$1.58M | ﹤0.01% | 4202 |
|
|
2021
Q1 | – | Sell |
-52,000
| Closed | -$4.56M | – | 5929 |
|
|
2020
Q4 | $4.56M | Buy |
+52,000
| New | +$4.12M | ﹤0.01% | 2537 |
|
|
2020
Q3 | – | Sell |
-50,000
| Closed | -$6.17M | – | 4458 |
|
|
2020
Q2 | $6.17M | Buy |
+50,000
| New | +$4.97M | 0.01% | 1578 |
|
|
2020
Q1 | – | Sell |
-50,000
| Closed | -$4.23M | – | 3873 |
|
|
2019
Q4 | $4.23M | Sell |
50,000
-150,000
| -75% | -$11.3M | 0.01% | 2067 |
|
|
2019
Q3 | $13.5M | Sell |
200,000
-25,000
| -11% | -$1.93M | 0.02% | 1062 |
|
|
2019
Q2 | $19.3M | Buy |
225,000
+25,000
| +13% | +$2.14M | 0.03% | 814 |
|
|
2019
Q1 | $17.8M | Buy |
+200,000
| New | +$18.5M | 0.03% | 877 |
|
|
2014
Q3 | – | Sell |
-44,600
| Closed | -$2.77M | – | 3692 |
|
|
2014
Q2 | $2.77M | Buy |
+44,600
| New | +$2.69M | 0.01% | 1564 |
|
|
2014
Q1 | – | Sell |
-42,500
| Closed | -$2.99M | – | 3453 |
|
|
2013
Q4 | $2.99M | Buy |
42,500
+3,100
| +8% | +$211K | 0.01% | 1534 |
|
|
2013
Q3 | $2.84M | Buy |
+39,400
| New | +$2.62M | 0.01% | 1470 |
|
Other funds holding BMRN
VPC
Israel Englander's BMRN Position: Q2 2026 in Review
Israel Englander reduced its BioMarin Pharmaceuticals (BMRN) stake by 31% in Q2 2026, selling an estimated $51.4M and leaving 2,071,816 shares worth $119M. The position accounts for 0.04% of the portfolio, ranked #444.
Israel Englander first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $199M in Q1 2024. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Israel Englander held 2,071,816 shares of BioMarin Pharmaceuticals worth $119M as of Q2 2026.
- Israel Englander sold 938,492 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $51.4M.
- BioMarin Pharmaceuticals made up 0.04% of Israel Englander's portfolio in Q2 2026, its #444 holding.
- Israel Englander first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Israel Englander's BioMarin Pharmaceuticals position peaked at $199M in Q1 2024.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.